- Liz Highleyman | 13 December 2012
Intensifying entecavir (Baraclude) treatment for hepatitis B by adding pegylated interferon
lowers HBV viral load and increases the likelihood of hepatitis B "e"
antigen (HBeAg) loss, according to a presentation at The ...
- Liz Highleyman | 12 December 2012
An
all-oral dual regimen of sofosbuvir (GS-7977) plus full-dose ribavirin was
well-tolerated and produced four-week post-treatment sustained response in
approximately three-quarters of previously untreated genotype 1 chronic
hepatitis C patients in an inner-city pilot ...
- Liz Highleyman | 05 December 2012
Real-world experience in the French early-access CUPIC
cohort shows that hepatitis C patients with advanced liver damage can achieve good
response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivo), researchers reported ...
- Liz Highleyman | 05 December 2012
The investigational cancer drug brivanib did not
significantly increase survival for people with hepatocellular carcinoma over
existing standard therapy, researchers reported at the recent Liver Meeting 2012, the 63rd Annual Meeting of ...
- Liz Highleyman | 03 December 2012
An all-oral regimen of
telaprevir, VX-222 and ribavirin for 12 weeks was generally well-tolerated and
produced sustained virological response in approximately 70% of previously
untreated chronic hepatitis C patients, according to findings from ...
- Liz Highleyman | 29 November 2012
Treatment
of chronic hepatitis B with nucleoside analogues including lamivudine (Epivir) and entecavir (Baraclude) can reduce the risk of
developing hepatocellular carcinoma, including cancer recurrence after
successful resection surgery, according to data presented ...
- Liz Highleyman | 23 November 2012
The hepatitis C protease inhibitor telaprevir (Incivo or Incivek)
taken twice daily with pegylated interferon plus ribavirin is as likely to
produce sustained virological suppression as the approved three-times-daily
schedule, with similar safety ...
- Rob Camp | 23 November 2012
Younger patients with advanced
liver disease caused by hepatitis C should be prioritised for treatment with newly licensed directly acting
antivirals to achieve the biggest reductions in ill health and hospitalisation,
according to ...
- Rob Camp | 23 November 2012
When resources for hepatitis C treatment with new directly acting
antivirals are limited, findings from the United States suggest that previously
untreated people with low viral loads may stand a good chance ...
- Liz Highleyman | 22 November 2012
Tenofovir (Viread)
continues to be safe and effective for treating chronic hepatitis B through eight
years of follow-up, researchers reported at The Liver Meeting 2012, the 63rd Annual Meeting
of the American Association ...
- Liz Highleyman | 21 November 2012
A 12-week, once-daily regimen of the
hepatitis C (HCV) polymerase inhibitor sofosbuvir and the NS5A inhibitor daclatasvir,
without interferon or ribavirin, produced sustained virological response rates
for
treatment-naive people in the 90 to
100% range, ...
- Keith Alcorn | 20 November 2012
The first major
data on interferon-free hepatitis C treatment in people with cirrhosis show
that treatment using BI-201335 – now known as faldaprevir – and BI-207127 with ribavirin can be
safe, and proved ...
- Liz Highleyman | 19 November 2012
The hepatitis C protease inhibitor simeprevir (formerly TMC435) was
generally safe and well tolerated in people with advanced liver fibrosis or
cirrhosis and improved sustained response rates when added to pegylated
interferon and ...
- Liz Highleyman | 15 November 2012
The hepatitis C polymerase inhibitor sofosbuvir
produced high rates of sustained virological response in genotype 1 patients when
combined with ribavirin and the HCV NS5A inhibitor GS-5885, according to data
presented this week ...
- Keith Alcorn | 13 November 2012
Twelve weeks of treatment with a three-drug
combination of new directly acting antivirals that contained neither pegylated
interferon nor ribavirin led to a sustained virologic response 12 weeks after
completion of treatment (SVR12) ...
- Liz Highleyman | 13 November 2012
Chronic hepatitis C patients treated with boceprevir (Victrelis) plus pegylated interferon and
ribavirin can effectively manage drug-induced anaemia by either ribavirin dose
reduction or addition of erythropoietin (EPO) without compromising treatment
effectiveness, researchers ...
- Keith Alcorn | 12 November 2012
Over 79% of previously untreated and null
responder patients with genotype 1a hepatitis infection achieved a sustained
virologic response twelve weeks after completing treatment (SVR12) with an
interferon-free combination of two or three ...
- Keith Alcorn | 12 November 2012
Although an interferon-free combination of
antiviral drugs developed by Bristol-Myers Squibb to treat hepatitis C was
highly effective in curing the infection in previous null responders to
treatment with HCV genotype 1b infection, ...
- Liz Highleyman | 12 November 2012
HIV/HCV co-infected
people treated with telaprevir (Incivo)
triple therapy are significantly more likely to achieve sustained virological
response, or a cure, than those treated with pegylated interferon/ribavirin
alone, according to final results from Study ...
- Liz Highleyman | 12 November 2012
The experimental hepatitis C
drugs danoprevir and mericitabine, with or without pegylated interferon and
ribavirin, showed good safety and efficacy in previously treated patients,
according to findings from the MATTERHORN study presented at ...